Back to top
more

STERIS (STE)

(Delayed Data from NYSE)

$223.87 USD

223.87
735,318

-4.56 (-2.00%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $223.90 +0.03 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Add STERIS (STE) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about STERIS (STE) on its strong segmental performance in Q3.

Zacks Equity Research

STERIS (STE) Stock Hits New 52-Week High: What's Driving it?

by Zacks Equity Research

STERIS (STE) is optimistic about maintaining growth momentum on broader product and service portfolio along with several tuck-in acquisitions.

Zacks Equity Research

STERIS' (STE) Growth Picture Impressive Amid Rising Costs

by Zacks Equity Research

STERIS (STE) growing steadily on favorable underlying market trends, along with new product and service offerings.

Zacks Equity Research

Insulet (PODD) Q4 Earnings Lag Estimates, Revenues Beat

by Zacks Equity Research

Insulet's (PODD) fourth-quarter 2019 results reflect strong segmental performances.

Zacks Equity Research

Intersect ENT (XENT) Reports Narrower-Than-Expected Q4 Loss

by Zacks Equity Research

Intersect ENT (XENT) exhibits a dismal performance in the fourth quarter of 2019.

Zacks Equity Research

Tandem Diabetes (TNDM) Q4 Earnings Beat Estimates, Margins Up

by Zacks Equity Research

Tandem Diabetes (TNDM) once again registers strong domestic pump shipment in Q4.

Zacks Equity Research

Teleflex (TFX) Earnings and Revenues Beat Estimates in Q4

by Zacks Equity Research

Teleflex's (TFX) fourth-quarter 2019 results reflect strong segmental performances.

Zacks Equity Research

Integra (IART) Q4 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

Integra's (IART) fourth-quarter 2019 results reflect strong segmental performances.

Zacks Equity Research

Globus Medical (GMED) Lags Q4 Earnings, Beats on Revenues

by Zacks Equity Research

Globus Medical (GMED) registers impressive growth within U.S. Spine on record recruiting of competitive representatives in Q4.

Zacks Equity Research

NuVasive (NUVA) Earnings and Revenues Beat Estimates in Q4

by Zacks Equity Research

NuVasive's (NUVA) Biologics business returns to growth in the fourth quarter of 2019.

Zacks Equity Research

Bruker (BRKR) Stock Rises on Strong Preliminary Q4 Show

by Zacks Equity Research

Bruker's (BRKR) revenue growth is expected to beat expectations for the fourth quarter and 2019.

Zacks Equity Research

Chemed (CHE) Q4 Earnings & Revenues Beat Estimates, Margins Up

by Zacks Equity Research

Chemed's (CHE) fourth-quarter 2019 results reflect strong segmental performances.

Zacks Equity Research

STERIS (STE) Surpasses Q3 Earnings Estimates, Ups FY20 View

by Zacks Equity Research

STERIS' (STE) third-quarter fiscal 2020 results reflect strong segmental performances.

Zacks Equity Research

Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Edwards Lifesciences (EW) Q4 Earnings Lag, Sales Top Estimates

by Zacks Equity Research

Edwards Lifesciences (EW) witnesses growth in TAVR procedures, led by strong therapy adoption across all geographies, particularly in the United States.

Zacks Equity Research

ResMed (RMD) Q2 Earnings Beat Estimates, Margins Expand

by Zacks Equity Research

ResMed (RMD) exhibits robust growth in the second quarter of fiscal 2020, fueled by the strong performance of both its segment.

Zacks Equity Research

IDEXX (IDXX) Q4 Earnings Top Estimates, Revenues Grow Y/Y

by Zacks Equity Research

The year-over-year upside in IDEXX's (IDXX) revenues was primarily driven by strong global gains in CAG Diagnostics' recurring revenues.

Zacks Equity Research

CONMED (CNMD) Earnings and Revenues Beat Estimates in Q4

by Zacks Equity Research

CONMED's (CNMD) fourth-quarter earnings gain from higher revenues and strong performance in General Surgery segment. However, high long-term debt remains a concern.

Zacks Equity Research

Quest Diagnostics (DGX) Q4 Earnings Beat, Margins Strong

by Zacks Equity Research

We are upbeat about Quest Diagnostics' (DGX) expanded network access, which assists the company to expedite volume growth in Q4.

Zacks Equity Research

Hologic (HOLX) Q1 Earnings Meet, Revenues Beat Estimates

by Zacks Equity Research

Hologic (HOLX) exhibits robust growth in first-quarter fiscal 2020, fueled by strong performance in the majority of its segments.

Zacks Equity Research

Illumina (ILMN) Q4 Earnings Beat Estimates, Margins Expand

by Zacks Equity Research

Illumina (ILMN) exhibits robust growth in the fourth quarter of fiscal 2019, fueled by strong performance of the sequencing consumable segment.

Zacks Equity Research

Thermo Fisher (TMO) Q4 Earnings Top, Organic Growth Solid

by Zacks Equity Research

We are upbeat that two of Thermo Fisher's (TMO) four business segments deliver strong year-over-year revenue growth in Q4.

Zacks Equity Research

AmerisourceBergen (ABC) Q1 Earnings Beat, Revenues Miss

by Zacks Equity Research

AmerisourceBergen's (ABC) Q1 earnings benefit from higher revenues, segmental growth and strong fiscal 2020 outlook.

Zacks Equity Research

Align Technology (ALGN) Earnings Beat in Q4, Margins Rise

by Zacks Equity Research

We are upbeat about Align Technology's (ALGN) continued momentum in Invisalign volumes across all geographies during Q4.

Zacks Equity Research

Stryker (SYK) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Stryker's (SYK) fourth-quarter earnings gain from higher revenues, solid segmental performance and strong organic growth across businesses benefit.